Back to Resources

Advancing Products and Awareness Highlighted in the Q2 2026 CIDP Market Review

Market Highlights

  • Argenx highlighted the anticipated Phase 3 readout for empasiprubart, Vyvgart’s market growth, and CIDP awareness.

  • Sanofi announced the discontinuation of a riliprubart trial and the review of another.

  • Takeda promoted CIDP awareness and dosing convenience with HyHub.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com

Get in Touch

Want to see what we can do for your organization? We’ll walk you through CDP, train your team, and stay close with ongoing support.

Contact us